(Q33417165)

26 July 2017

Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation (English)

1 reference

atypical hemolytic uremic syndrome

26 July 2017

1 reference

3

Eiji Ishikawa

1 reference

26 July 2017

Takeshi Matsumoto

1

1 reference

26 July 2017

Xinping Fan

2

1 reference

26 July 2017

Masaaki Ito

4

1 reference

26 July 2017

Keishirou Amano

5

1 reference

26 July 2017

Hidemi Toyoda

6

1 reference

26 July 2017

Yoshihiro Komada

7

1 reference

26 July 2017

Kohshi Ohishi

8

1 reference

26 July 2017

Naoyuki Katayama

9

1 reference

26 July 2017

Yoko Yoshida

10

1 reference

26 July 2017

Masanori Matsumoto

11

1 reference

26 July 2017

Yoshihiro Fujimura

12

1 reference

26 July 2017

Makoto Ikejiri

13

1 reference

26 July 2017

Hideo Wada

14

1 reference

26 July 2017

Toshiyuki Miyata

15

1 reference

26 July 2017

19 August 2014

1 reference

International Journal of Hematology

26 July 2017

1 reference

26 July 2017

100

1 reference

26 July 2017

5

1 reference

26 July 2017

437-442

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-014-1655-2

26 July 2017

0 references

cites work

Escherichia coli O157:H7 and the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Thrombotic Microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Alternative complement pathway assessment in patients with atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Membranoproliferative glomerulonephritis--a new look at an old entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

National questionnaire survey of TMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

A second national questionnaire survey of TMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1655-2

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25135378

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12185-014-1655-2

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference